Immuron Ltd — Share Issue/Capital Change 2012

May 2, 2012

==> picture [188 x 41] intentionally omitted <==

ABN: 80 063 114 045 Level 1, 39 Leveson Street North Melbourne, Vic 3051 Tel: +61 3 8637 1107 Fax: +61 3 9328 1675 www.immuron.com

IMMURON CLARIFIES BONUS OPTIONS TO SHAREHOLDERS

3 May 2012, Melbourne: Australian biopharmaceutical company Immuron Limited (ASX: IMC) provides clarification of its bonus option offer announced on 23 April following a number of enquiries from investors:

• One new option will be granted for every four ordinary shares held by shareholders on the company’s register as at 5pm 23 July 2012.

• The options will be issued for free.

• The options will be exercisable at 4 cents any time before 5pm 30 April 2015.

• A prospectus will be issued to facilitate the issue of the bonus options.

• The company will apply for the options to be quoted on ASX.

Immuron is delighted to announce this bonus issue as an appreciative gesture to its loyal shareholder base, especially as the company expects several commercialisation milestones in the short to medium term.

Contact Joe Baini Rudi Michelson Chief Executive Officer Monsoon Communications +61 3 8637 1107 +61 3 9620 3333 0411 402 737

About Immuron Limited

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron is uniquely positioned with a versatile technology platform capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre-clinical studies relatively quickly and increases the prospect that the clinical development of Immuron’s products will be expedited. Immuron’s current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as fatty liver (NASH), and the prevention of influenza. Immuron has one product in the market, Travelan, for preventing travelers’ diarrhoea. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel), the University of Melbourne and Monash University (Australia).

1